{"filings":[{"id":499876,"accession_number":"0001401914-26-000030","cik":1401914,"company_name":"Dare Bioscience, Inc.","ticker":"DARE","form_type":"8-K","filed_at":"2026-05-18T20:25:47+00:00","items":["3.02"],"status":"ready","headline":"Daré Bioscience closes Reg A offering, raises $250K from 50,000 units at $5/unit","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 50,000 Investor Units at $5.00 each, total gross proceeds $250,000.","Each unit includes one share of Series A Convertible Preferred Stock and two warrants.","Warrants to purchase up to 100,000 shares of common stock.","Offering circular qualified by SEC on April 1, 2026; closings on May 14, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":33718857.39828326,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":442363,"accession_number":"0001401914-26-000025","cik":1401914,"company_name":"Dare Bioscience, Inc.","ticker":"DARE","form_type":"8-K","filed_at":"2026-05-14T20:01:25+00:00","items":["2.02","9.01"],"status":"ready","headline":"Daré Bioscience reports Q1 2026 cash $18.5M; first product revenue expected June 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and equivalents $18.5M as of March 31; working capital ~$0.5M; revenue $0.2M from Gates Foundation services.","Ovaprene Phase 3 trial receives second positive DSMB review; enrollment expected to complete in 2026 with 2027 primary endpoint analysis.","DARE to PLAY sildenafil cream dispensing to commence summer 2026; pre-fulfillment prescribing active in all 50 states.","Flora Sync LF5 commercial launch in June 2026; first-ever product revenue milestone expected that month.","DARE-HPV Phase 2 study starting May 2026 with ARPA-H funding; DARE to RECLAIM targeting 2027 dispensing."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.21,"consensus_revenue_estimate":null,"consensus_revenue_actual":152455.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":33718857.39828326,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":92644,"accession_number":"0001401914-26-000021","cik":1401914,"company_name":"Dare Bioscience, Inc.","ticker":"DARE","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["3.02"],"status":"ready","headline":"Daré Bioscience closes $975k Regulation A offering of Series A Preferred and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 195,010 Investor Units at $5.00 each, each unit consisting of one Series A Preferred share and two common stock warrants.","Total gross proceeds approximately $975,050 from closings on May 1,4,5,6, 2026.","Warrants to purchase up to 390,020 shares of common stock, terms as previously reported in Jan 29 2026 8-K.","Offering conducted under qualified Form 1-A (File No. 024-12688)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":33718857.39828326,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":92643,"accession_number":"0001493152-26-018460","cik":1401914,"company_name":"Dare Bioscience, Inc.","ticker":"DARE","form_type":"8-K","filed_at":"2026-04-22T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Daré Bioscience posts updated corporate presentation on investor website","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Presentation dated April 22, 2026, furnished as Exhibit 99.1.","No material financial or operational updates specified in the 8-K body.","Presentation content not provided; confidence in news value is low."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":33718857.39828326,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":92642,"accession_number":"0001401914-26-000012","cik":1401914,"company_name":"Dare Bioscience, Inc.","ticker":"DARE","form_type":"8-K","filed_at":"2026-04-20T23:59:59+00:00","items":["3.02"],"status":"ready","headline":"Daré Bioscience closes $100K Reg A offering of 20,000 units at $5/unit","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 20,000 Investor Units, each: one share Series A Convertible Preferred + two warrants for common stock.","Gross proceeds of $100,000 from 20,000 units at $5.00 per unit.","Investor warrants exercisable for up to 40,000 shares of common stock.","Offering statement qualified by SEC on April 1, 2026; terms previously reported in Jan 29, 2026 8-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":33718857.39828326,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":92641,"accession_number":"0001401914-26-000010","cik":1401914,"company_name":"Dare Bioscience, Inc.","ticker":"DARE","form_type":"8-K","filed_at":"2026-04-17T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Gregory W. Matz reclassified from Class II to Class III director to rebalance board classes","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Matz resigned as Class II director and was reappointed as Class III director effective April 16, 2026.","Reclassification was solely to rebalance the three board classes; service deemed uninterrupted.","Board remains at six members; Matz and Sabrina Martucci Johnson will stand for election at 2026 annual meeting.","No changes to Matz's committee assignments as a result of the reclassification."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":33718857.39828326,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":92640,"accession_number":"0001401914-26-000006","cik":1401914,"company_name":"Dare Bioscience, Inc.","ticker":"DARE","form_type":"8-K","filed_at":"2026-04-13T23:59:59+00:00","items":["3.02"],"status":"ready","headline":"Daré Bioscience closes Reg A offering, issues 3,470 units at $5.00 each","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Closed on April 10, 2026: issued 3,470 Investor Units, each at $5.00, for gross proceeds of $17,350.","Each unit contains one share of Series A Convertible Preferred Stock and two warrants to purchase 6,940 common shares total.","Offering qualified by SEC on April 1, 2026; previously disclosed in Form 8-K filed January 29, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":33718857.39828326,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103620,"accession_number":"0001493152-26-012902","cik":1401914,"company_name":"Dare Bioscience, Inc.","ticker":"DARE","form_type":"8-K","filed_at":"2026-03-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Daré Bioscience FY2025: $24.7M cash, $20.8M equity proceeds; DARE to PLAY revenue expected Q2 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and cash equivalents $24.7M at Dec 31, 2025; working capital $3.4M.","Received $20.8M net from at-the-market equity program and equity line in 2025.","Non-dilutive funding: $13.6M Gates Foundation, $4.5M ARPA-H, $1.3M NIH in 2025.","SG&A $8.8M (down from $9.2M in 2024); R&D $5.5M (down from $14.3M); contra-R&D $16.4M from grants.","Expects DARE to PLAY product revenue and Flora Sync LF5 consumer revenue to begin Q2 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":33718857.39828326,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103619,"accession_number":"0001493152-26-010594","cik":1401914,"company_name":"Dare Bioscience, Inc.","ticker":"DARE","form_type":"8-K","filed_at":"2026-03-17T23:59:59+00:00","items":["3.02"],"status":"ready","headline":"Daré Bioscience closes $215K Regulation A offering of Series A Preferred Stock and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 43,050 Investor Units at $5.00/unit; each unit contains one share of Series A Convertible Preferred and two common stock purchase warrants.","Total gross proceeds of approximately $215,250; warrants exercisable for up to 86,100 shares of common stock.","Offering qualified by SEC on January 5, 2026 under Regulation A; terms previously reported in Form 8-K filed January 29, 2026.","Proceeds provide additional working capital for the company's development programs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":33718857.39828326,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103618,"accession_number":"0001493152-26-009364","cik":1401914,"company_name":"Dare Bioscience, Inc.","ticker":"DARE","form_type":"8-K","filed_at":"2026-03-09T23:59:59+00:00","items":["3.02"],"status":"ready","headline":"Daré Bioscience closes second tranche of Regulation A offering, issuing 17,500 units at $5.00","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 17,500 Investor Units at $5.00 each, raising $87,500 in gross proceeds.","Each unit includes one share of Series A Convertible Preferred Stock and two warrants to purchase common stock.","Warrants are exercisable for up to 35,000 shares of common stock in total.","Offering is being conducted under qualified Form 1-A (File No. 024-12688) with offering circular dated January 6, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":33718857.39828326,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103617,"accession_number":"0001493152-26-008451","cik":1401914,"company_name":"Dare Bioscience, Inc.","ticker":"DARE","form_type":"8-K","filed_at":"2026-03-02T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Daré Bioscience posts updated corporate presentation; no specific details in filing","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Updated corporate presentation made available on company website on March 2, 2026.","Presentation furnished as Exhibit 99.1; content not reproduced in this filing.","No financial or operational metrics disclosed in the 8-K body itself."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":33718857.39828326,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103616,"accession_number":"0001493152-26-004245","cik":1401914,"company_name":"Dare Bioscience, Inc.","ticker":"DARE","form_type":"8-K","filed_at":"2026-01-29T23:59:59+00:00","items":["3.02","8.01","3.03","5.03","9.01"],"status":"ready","headline":"Daré Bioscience closes initial tranche of Reg A offering at $5/unit; issues 5,090 units","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Initial closing on Jan 27, 2026: issued 5,090 Units (each 1 share Series A Preferred + 2 warrants) for $25,450 gross proceeds.","Series A Preferred convertible at $2.50/share, no dividends, liquidation preference $5/share, senior to common stock.","Investor warrants exercisable at $4.00/share for 36 months; Agent warrants at $6.25/unit, subject to 180-day lock-up.","Company can call preferred after 3 years at lesser of stated value + 8% annual or 200% of stated value.","Forced conversion triggers: change of control, stock price ≥$4.50 for 10 of 30 days, or firm IPO ≥$15M at ≥$4.50."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":33718857.39828326,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103615,"accession_number":"0001493152-26-000513","cik":1401914,"company_name":"Dare Bioscience, Inc.","ticker":"DARE","form_type":"8-K","filed_at":"2026-01-06T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Daré Bioscience posts updated corporate presentation; no material new info disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Filed under Item 7.01; presentation available on company website and as Exhibit 99.1.","No specific financial or operational updates provided in the filing body.","Presentation content not available for review; confidence in material new facts is low."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":33718857.39828326,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119882,"accession_number":"0001493152-25-025491","cik":1401914,"company_name":"Dare Bioscience, Inc.","ticker":"DARE","form_type":"8-K","filed_at":"2025-12-01T23:59:59+00:00","items":["1.02","7.01","9.01"],"status":"ready","headline":"Bayer terminates Ovaprene license; Daré regains full rights, Phase 3 study continues","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Bayer HealthCare terminated Ovaprene license agreement effective Feb 24, 2026 due to strategic prioritization.","Daré regains full commercialization rights to Ovaprene, a hormone-free monthly intravaginal contraceptive.","Pivotal Phase 3 study continues with positive interim data (July 2025) and Gates Foundation grant support.","Enrollment expected to complete in 2026; no change to timelines or operations.","Daré to explore partnerships and strategic transactions for Ovaprene."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":33718857.39828326,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119881,"accession_number":"0001493152-25-022277","cik":1401914,"company_name":"Dare Bioscience, Inc.","ticker":"DARE","form_type":"8-K","filed_at":"2025-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"DARE Bioscience reports Q3 cash $23.1M; Sildenafil Cream on track for Dec launch via 503B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and equivalents $23.1M; working capital $3.8M as of Sep 30, 2025.","R&D expense $1.2M (down 56% YoY) due to grant funding; G&A $2.5M (up 25% YoY) on commercial readiness.","DARE to PLAY Sildenafil Cream on track for initial Rx fulfillment Dec 2025 via 503B compounding (near-term revenue).","Positive DSMB recommendation for Ovaprene Phase 3 study; enrollment continues.","Received $6M (Jul) and $4M (Oct) grant installments for DARE-LARC1; $3.6M expected for DARE-NHC in Nov 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.18,"consensus_revenue_estimate":null,"consensus_revenue_actual":6517.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":33718857.39828326,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136449,"accession_number":"0001493152-25-012516","cik":1401914,"company_name":"Dare Bioscience, Inc.","ticker":"DARE","form_type":"8-K","filed_at":"2025-09-02T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Daré Bioscience provides corporate presentation; no specific data disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Presentation dated September 2, 2025 filed as exhibit; full content not included in 8-K.","No new financial or operational details available from this filing for summary.","Presentation intended for investor meetings; available on Daré's IR website.","Investors should consult company website for complete presentation content."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":33718857.39828326,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136448,"accession_number":"0001641172-25-023971","cik":1401914,"company_name":"Dare Bioscience, Inc.","ticker":"DARE","form_type":"8-K","filed_at":"2025-08-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Daré Bioscience Q2 2025: Cash $5.0M, Sildenafil Cream launch on track for Q4 2025, Ovaprene DSMB positive","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash of $5.0M at June 30; working capital deficit $12.6M; raised ~$17.6M net from ATM and $6M grant post-quarter.","G&A $2.4M, R&D $1.4M (down 71% YoY) reflecting increased contra R&D from grants.","DARE to PLAY Sildenafil Cream on track for Q4 2025 launch via 503B compounding, targeting near-term revenue.","Ovaprene Phase 3 DSMB recommended continuation no new safety concerns; interim pregnancy rate consistent.","DARE-HRT1 monthly ring pursuing 503B compounding for late 2026 alongside FDA pathway."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.95,"consensus_revenue_estimate":null,"consensus_revenue_actual":4255.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":33718857.39828326,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136447,"accession_number":"0001493152-25-011402","cik":1401914,"company_name":"Dare Bioscience, Inc.","ticker":"DARE","form_type":"8-K","filed_at":"2025-07-25T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Daré Bioscience regains Nasdaq compliance but faces one-year Mandatory Panel Monitor","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq letter confirming compliance with stockholders' equity rule (Nasdaq 5550(b)(1)) on July 24, 2025.","Subject to Mandatory Panel Monitor for one year from July 24, 2025.","If non-compliance within year, delist determination with no right to submit compliance plan or cure period."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":33718857.39828326,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136446,"accession_number":"0001641172-25-020295","cik":1401914,"company_name":"Dare Bioscience, Inc.","ticker":"DARE","form_type":"8-K","filed_at":"2025-07-21T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Dare Bioscience raises $16.5M, believes it regains Nasdaq equity compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Raised approx. $16.5M gross from ATM and equity line sales since Mar 31, 2025.","Believes stockholders' equity now exceeds $2.5M Nasdaq minimum for continued listing.","Will notify Nasdaq; no guarantee of regaining compliance.","Shares outstanding will be ~12.6M after the sales."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":33718857.39828326,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136445,"accession_number":"0001641172-25-018894","cik":1401914,"company_name":"Dare Bioscience, Inc.","ticker":"DARE","form_type":"8-K","filed_at":"2025-07-14T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Daré's Ovaprene Phase 3 interim shows ~9% pregnancy rate; DSMB OK to continue","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["DSMB recommended study continue without modification after planned interim safety analysis.","~9% of treated women had experienced a pregnancy, consistent with company expectations.","~17% discontinued due to vaginal odor; no serious safety concerns or new tolerability issues.","~115 of target ~250 participants ongoing/completed; final primary endpoint uses Pearl Index.","Bayer can obtain U.S. commercialization rights with $20M payment, plus up to $310M milestones and tiered royalties."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":33718857.39828326,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136444,"accession_number":"0001641172-25-018393","cik":1401914,"company_name":"Dare Bioscience, Inc.","ticker":"DARE","form_type":"8-K","filed_at":"2025-07-09T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Dare Bioscience shareholders approve 600,000-share increase to 2022 stock plan; re-elect directors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders re-elected directors Matz, Rastetter, and Steele; each received >2.4M votes for.","Ratified Haskell & White LLP as independent auditor for FY2025 with 4.5M votes for, 106K against.","Advisory say-on-pay resolution approved with 2.38M votes for, 243K against.","Approved amendment increasing shares reserved under 2022 Stock Incentive Plan by 600,000 to 1,383,333."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":33718857.39828326,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153609,"accession_number":"0001641172-25-016374","cik":1401914,"company_name":"Dare Bioscience, Inc.","ticker":"DARE","form_type":"8-K","filed_at":"2025-06-25T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Nasdaq panel approves Dare Bioscience's compliance plan; deadline Aug 12, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Panel approved modified plan to regain compliance with Nasdaq Listing Rules 5550(b)(1) (≥$2.5M equity) or 5550(b)(2) (≥$35M MVLS).","Must demonstrate compliance by July 31, 2025; conditional listing ends August 12, 2025.","If plan fails, Nasdaq may delist common stock before August 12, 2025.","Company has been non-compliant with Rule 5550(b) since August 2024.","No assurances given that compliance will be achieved by the deadlines."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":33718857.39828326,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153608,"accession_number":"0001641172-25-014238","cik":1401914,"company_name":"Dare Bioscience, Inc.","ticker":"DARE","form_type":"8-K","filed_at":"2025-06-09T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Dare Bioscience provides corporate presentation; filing text lacks specific content","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Corporate presentation dated June 9, 2025 furnished as Exhibit 99.1.","Presentation to be used in meetings with market participants and available on company website.","No specific financial, pipeline, or guidance updates disclosed in the provided filing text."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":33718857.39828326,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153607,"accession_number":"0001641172-25-009939","cik":1401914,"company_name":"Dare Bioscience, Inc.","ticker":"DARE","form_type":"8-K","filed_at":"2025-05-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Daré Bioscience Q1 2025: Cash $10.3M, R&D down 31%, expects first revenue in Q4 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and equivalents $10.3M at March 31, 2025; working capital deficit of $9.4M.","R&D expenses fell 31% YoY to $2.3M; G&A expenses decreased to $2.3M from $2.7M.","Targeting first revenue in Q4 2025 via Sildenafil Cream as 503B compounded drug; DARE-HRT1 in 2026.","Ovaprene Phase 3 contraceptive efficacy study ongoing; interim DSMB review scheduled for July 2025.","Strategy shift: dual path of 503B compounding and FDA approval; aiming for four on-market products by 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.5,"consensus_revenue_estimate":null,"consensus_revenue_actual":25427.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":33718857.39828326,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153606,"accession_number":"0001641172-25-003887","cik":1401914,"company_name":"Dare Bioscience, Inc.","ticker":"DARE","form_type":"8-K","filed_at":"2025-04-11T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Nasdaq grants Daré extension until Aug 12, 2025 to regain listing compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Extension conditional on meeting stockholders' equity >$2.5M by April 30, 2025 and further increase by July 15, 2025.","Company must publicly disclose equity-raising transactions and provide 12-month projections by August 12, 2025.","Non-compliance with Nasdaq Rule 5550(b) since August 2024; risk of delisting if conditions not met.","Panel may reconsider extension or delist after April 30 if plan execution falters."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":33718857.39828326,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172316,"accession_number":"0001641172-25-001682","cik":1401914,"company_name":"Dare Bioscience, Inc.","ticker":"DARE","form_type":"8-K","filed_at":"2025-03-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Dare Bioscience reports FY2024 cash $15.7M, plans Sildenafil Cream 503B launch in Q4 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and equivalents $15.7M at Dec 31, 2024; working capital deficit of $3.2M.","G&A expenses $9.2M (down 24% YoY); R&D expenses $14.2M (down 34% YoY).","Plans to make proprietary Sildenafil Cream 3.6% available via 503B compounding in Q4 2025; expects revenue and cash flow from Q4.","Ovaprene Phase 3 contraceptive study ongoing; half of 125 participants to complete ~6 months by Q2 2025 for interim DSMB review.","DARE-LARC1 received $3.5M grant in 2024; total $31.8M of up to $49M foundation grant received to date."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.5,"consensus_revenue_estimate":null,"consensus_revenue_actual":25427.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":33718857.39828326,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172315,"accession_number":"0001493152-25-006958","cik":1401914,"company_name":"Dare Bioscience, Inc.","ticker":"DARE","form_type":"8-K","filed_at":"2025-02-14T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Dare Bioscience receives Nasdaq delisting notice for failing to meet $35M minimum MVLS rule","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["On Feb 13, 2025, Nasdaq notified Dare Bioscience that its common stock is subject to delisting for failure to regain compliance with the Minimum MVLS Rule by Feb 10, 2025.","The company will request a hearing before the Nasdaq Hearing Panel, which will stay the delisting pending the Panel's decision.","Hearings typically scheduled 30-45 days after request; Panel decision expected within 30 days of hearing; no assurance of extension granted.","Original deficiency notice received Aug 12, 2024; company had 180 days to regain compliance but failed to meet the $35M market value requirement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":33718857.39828326,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172314,"accession_number":"0001493152-25-005533","cik":1401914,"company_name":"Dare Bioscience, Inc.","ticker":"DARE","form_type":"8-K","filed_at":"2025-02-10T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Daré Bioscience furnishes corporate presentation at BIO CEO Conference; no specific financial details disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Presentation dated February 10, 2025, used at BIO CEO & Investor Conference in New York.","Presentation made available on company's investor relations website.","No material financial results, guidance, or operational updates provided in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":33718857.39828326,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172313,"accession_number":"0001493152-25-001871","cik":1401914,"company_name":"Dare Bioscience, Inc.","ticker":"DARE","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Dare Bioscience furnishes corporate presentation; specific details unavailable","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Corporate presentation dated January 13, 2025 furnished under Item 7.01.","Presentation to be used in meetings with securities market participants starting January 13, 2025.","Presentation also to be posted on Daré's investor relations website under Presentations section.","No specific financial or operational data from the presentation included in the 8-K filing text.","Filing does not contain material new information beyond the fact of the presentation itself."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":33718857.39828326,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189310,"accession_number":"0001493152-24-050117","cik":1401914,"company_name":"Dare Bioscience, Inc.","ticker":"DARE","form_type":"8-K","filed_at":"2024-12-16T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Daré announces Phase 3 plans for Sildenafil Cream for FSAD; protocol submission in Q1 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Will submit Phase 3 protocol and statistical plan to FDA in Q1 2025; target mid-2025 to start the study.","A second confirmatory Phase 3 study will be required for NDA submission.","Phase 3 co-primary endpoints are arousal sensations and associated distress, same as Phase 2b RESPOND study.","Sildenafil Cream has potential to be first FDA-approved pharmacological treatment for FSAD (no current approved options).","Market research estimates ~10M U.S. women distressed by FSAD symptoms actively seeking solutions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":33718857.39828326,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189309,"accession_number":"0001493152-24-045860","cik":1401914,"company_name":"Dare Bioscience, Inc.","ticker":"DARE","form_type":"8-K","filed_at":"2024-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Daré Bioscience Q3 2024: cash $11.2M; grants up to $10.7M and $10M; pipeline advancing","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and equivalents $11.2M at Sept 30, 2024; R&D expenses fell 60% YoY to $2.7M; G&A $2.0M.","Foundation grant of up to ~$10.7M for novel non-hormonal contraceptive and to add Ovaprene Phase 3 sites.","ARPA-H award of $10M for DARE-HPV IND-enabling activities; NICHD grant of $2M for DARE-PTB1.","Ovaprene Phase 3 enrolling at 10 US sites; target ~125 women completing 6 mo by Q2 2025.","Sildenafil Cream Phase 3 discussions with FDA ongoing; each Phase 3 study est. ~$15M direct costs."],"consensus_eps_estimate":null,"consensus_eps_actual":0.17,"consensus_revenue_estimate":null,"consensus_revenue_actual":73431.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":33718857.39828326,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189308,"accession_number":"0001493152-24-042455","cik":1401914,"company_name":"Dare Bioscience, Inc.","ticker":"DARE","form_type":"8-K","filed_at":"2024-10-25T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Daré Bioscience makes corporate presentation available to investors","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Company filed a corporate presentation dated October 25, 2024 as Exhibit 99.1.","Presentation will be used in meetings with investors and analysts starting October 25, 2024.","Copy available on company's investor relations website under Presentations section.","No specific financial or pipeline updates disclosed in the filing; presentation content not provided.","Filing is routine Regulation FD disclosure; no material new information can be confirmed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":33718857.39828326,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189307,"accession_number":"0001493152-24-042193","cik":1401914,"company_name":"Dare Bioscience, Inc.","ticker":"DARE","form_type":"8-K","filed_at":"2024-10-23T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Daré Bioscience awarded $10M from ARPA-H to develop HPV treatment candidate DARE-HPV","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Award of $10M from ARPA-H Sprint for Women's Health; milestone-based payments over 24 months.","DARE-HPV: investigational fixed-dose lopinavir/ritonavir vaginal insert for HPV-related cervical diseases.","Milestones include IND-enabling studies, FDA IND clearance, clinical supplies, and Phase 2 trial start.","More than half of award payable in first 12 months; ARPA-H retains certain IP rights including march-in."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":33718857.39828326,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189306,"accession_number":"0001493152-24-041796","cik":1401914,"company_name":"Dare Bioscience, Inc.","ticker":"DARE","form_type":"8-K","filed_at":"2024-10-21T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"Daré Bioscience secures $15M common stock purchase facility with Lincoln Park Capital","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered $15M common stock purchase agreement with Lincoln Park Capital Fund, LLC.","Daré has sole discretion to sell up to $15M shares over 24 months; LPC obligated to buy at market-based prices.","Proceeds intended to help fund Phase 3 program for Sildenafil Cream, 3.6% (estimated $15M direct costs).","Issued 137,614 commitment shares to LPC; no warrants issued, no short selling permitted.","Daré may terminate agreement at any time with no cost or penalty."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":33718857.39828326,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205801,"accession_number":"0001493152-24-031252","cik":1401914,"company_name":"Dare Bioscience, Inc.","ticker":"DARE","form_type":"8-K","filed_at":"2024-08-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Dare Bioscience Q2 cash $16.4M; Ovaprene Phase 3 enrolling; Sildenafil Cream awaits FDA feedback","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and equivalents $16.4M at June 30, 2024; received $22M non-dilutive royalty financing from XOMA in April 2024.","G&A expenses $2.4M, down 17% YoY; R&D expenses $4.9M, down 19% YoY.","Ovaprene Phase 3 contraceptive study recruiting at 20 U.S. sites; ~125 women expected to complete 6 months by Q2 2025.","Sildenafil Cream Phase 3 design pending additional FDA feedback; each Phase 3 study estimated at ~$15M.","Total grants received for DARE-LARC1 now ~$29.3M; pipeline includes DARE-HRT1 in development."],"consensus_eps_estimate":null,"consensus_eps_actual":0.72,"consensus_revenue_estimate":null,"consensus_revenue_actual":31740.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":33718857.39828326,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205800,"accession_number":"0001493152-24-028443","cik":1401914,"company_name":"Dare Bioscience, Inc.","ticker":"DARE","form_type":"8-K","filed_at":"2024-07-19T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Daré regains Nasdaq minimum bid price compliance, delisting risk removed","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Daré that closing bid price was ≥$1.00 for 10 consecutive sessions; compliance achieved.","Regaining compliance avoids potential delisting from Nasdaq Capital Market, strengthening market position.","Enrolling participants in pivotal Phase 3 study of Ovaprene for hormone-free monthly contraceptive candidate.","Continuing activities to progress Sildenafil Cream 3.6% Phase 3 pivotal studies for female sexual arousal disorder.","Awaiting additional FDA feedback on endpoints and safety database requirements for NDA submission."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":33718857.39828326,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222786,"accession_number":"0001493152-24-025435","cik":1401914,"company_name":"Dare Bioscience, Inc.","ticker":"DARE","form_type":"8-K","filed_at":"2024-06-27T23:59:59+00:00","items":["3.03","5.03","7.01","8.01","9.01"],"status":"ready","headline":"Daré Bioscience announces 1-for-12 reverse stock split effective July 1, 2024 to regain Nasdaq compliance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["1-for-12 reverse stock split effective July 1, 2024; shares reduce from ~101.1M to ~8.4M.","Purpose: regain compliance with Nasdaq $1.00 minimum bid price requirement.","Stockholder authorization obtained at June 5, 2024 annual meeting; Board set ratio at 1-for-12.","No fractional shares issued; fractional interests rounded up to next whole share after aggregation.","New CUSIP 23666P200; stock continues trading as DARE on Nasdaq."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":33718857.39828326,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222785,"accession_number":"0001493152-24-023097","cik":1401914,"company_name":"Dare Bioscience, Inc.","ticker":"DARE","form_type":"8-K","filed_at":"2024-06-07T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Daré Bioscience Announces Results of 2024 Annual Meeting, Stockholders Approve Reverse Split Authorization","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Re-elected directors Jessica D. Grossman, M.D. (28,626,331 for) and Susan L. Kelley, M.D. (28,623,481 for) as Class I directors.","Ratified Haskell & White LLP as independent auditor for FY2024 with 53,420,221 votes for, 1,624,718 against.","Advisory approval of named executive officer compensation received 26,182,433 votes for, 3,556,256 against, 594,264 abstentions.","Approved reverse stock split authorization at ratio between 1-for-2 and 1-for-12, with 42,657,404 for, 10,792,335 against.","Approved meeting adjournment proposal to solicit additional proxies if needed, with 44,780,743 votes for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":33718857.39828326,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222784,"accession_number":"0001493152-24-019087","cik":1401914,"company_name":"Dare Bioscience, Inc.","ticker":"DARE","form_type":"8-K","filed_at":"2024-05-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Daré Bioscience Q1 cash $3.6M, secures $22M royalty financing; Ovaprene Phase 3 ongoing","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash & equivalents $3.6M at March 31, 2024; subsequent $22M non-dilutive royalty financing from XOMA and $1M grant installment.","R&D expenses $3.3M in Q1 2024, down 34% YoY from $5.0M; G&A $2.7M vs $3.3M.","Ovaprene Phase 3 contraceptive study recruiting at 18 US sites; central ad campaign launched March 2024.","Sildenafil Cream end-of-Phase 2 meeting with FDA completed; additional feedback expected 2Q2024 for Phase 3 design.","XACIATO commercialized by Organon since Q4 2023; first FDA-approved product from Daré portfolio."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":9302.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":33718857.39828326,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222783,"accession_number":"0001493152-24-017147","cik":1401914,"company_name":"Dare Bioscience, Inc.","ticker":"DARE","form_type":"8-K","filed_at":"2024-04-30T23:59:59+00:00","items":["1.01","2.01","2.03","7.01","9.01"],"status":"ready","headline":"Daré Bioscience secures $22M non-dilutive royalty financing from XOMA for XACIATO and Phase 3 candidates","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["XOMA paid $22M upfront for 100% of Daré's net XACIATO royalties and milestones (after deductions); Daré also sold minority interest in Ovaprene/Sildenafil future revenue.","After XOMA achieves pre-specified return, Daré receives 50% of each successive $22M received (upside-sharing).","Synthetic royalties: 4% on Ovaprene net sales, 2% on Sildenafil Cream net sales, decreasing to 2.5% and 1.25% after further return threshold.","Total royalty-based capital committed ($34M) includes previous UiE financing; Daré retains significant majority of future economics.","Proceeds to fund Phase 3 pivotal programs for Ovaprene (contraceptive) and Sildenafil Cream (female sexual arousal disorder)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":33718857.39828326,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242270,"accession_number":"0001493152-24-011615","cik":1401914,"company_name":"Dare Bioscience, Inc.","ticker":"DARE","form_type":"8-K","filed_at":"2024-03-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Daré Bioscience reports FY2023 net loss $30.1M, cash $10.5M; XACIATO launched, Ovaprene Phase 3 recruiting","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $30.1M for FY2023; revenue of $2.8M from XACIATO milestone payments.","Cash and equivalents $10.5M at Dec 31, 2023; received $4.7M in grant funding and $17M in offerings/financing.","XACIATO launched in U.S. via Organon; Daré eligible for double-digit royalties and up to $180M milestones.","Ovaprene Phase 3 pivotal study recruiting at 17 U.S. sites; non-hormonal monthly contraceptive candidate.","Sildenafil Cream completed Phase 2b; FDA feedback on Phase 3 design expected in Q2 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":33718857.39828326,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}